Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065).
D000328:Adult; D000368:Aged; D001806:Blood Urea Nitrogen; D002813:Chondrosarcoma / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004273:DNA, Neoplasm / Q000096:biosynthesis; D003864:Depression, Chemical; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use*; D066298:In Vitro Techniques; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000378:metabolism; D007948:Leukemia, Monocytic, Acute / Q000378:metabolism; D007962:Leukocytes / Q000378:metabolism; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism; D008297:Male; D008441:Maxillary Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D013053:Spectrophotometry; D013921:Thrombocytopenia / Q000139:chemically induced; D013936:Thymidine / Q000378:metabolism; D014062:Tongue Neoplasms / Q000188:drug therapy; D014316:Tritium; D014839:Vomiting / Q000139:chemically induced
D004273:DNA, Neoplasm; D014316:Tritium; D013936:Thymidine; D006918:Hydroxyurea